Divestiture • Medical Products

Unicycive Therapeutics Acquires Renazorb

On December 14, 2020, Unicycive Therapeutics acquired medical products company Renazorb from Spectrum Pharmaceuticals

Acquisition Context
  • This is Unicycive Therapeutics’ 1st transaction in the Medical Products sector.
  • This is Unicycive Therapeutics’ 1st transaction in the United States.
  • This is Unicycive Therapeutics’ 1st transaction in Nevada.

Explore All 633 Divestiture Medical Products Deals - Search the Database Free


M&A Deal Summary

Date December 14, 2020
Target Renazorb
Sector Medical Products
Buyer(s) Unicycive Therapeutics
Sellers(s) Spectrum Pharmaceuticals
Deal Type Divestiture

Target Company

Renazorb

Henderson, Nevada, United States
Renazorb is a non-aluminum, non-calcium, phosphate binder manufactured using a patent-protected nanotechnology process. Renazorb is based in Henderson, Nevada.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Unicycive Therapeutics

Los Altos, California, United States

Category Company
Founded 2016
Sector Life Science
Employees14
Revenue 1M USD (2023)
DESCRIPTION

Unicycive Therapeutics is a biotechnology company developing novel treatments across multiple therapeutic areas, currently focusing on kidney diseases. Unicycive Therapeutics is based in Los Altos, California.


Deal Context for Buyer #
Overall 1 of 1
Sector: Medical Products 1 of 1
Type: Divestiture 1 of 1
State: Nevada 1 of 1
Country: United States 1 of 1
Year: 2020 1 of 1

Seller Profile 1

SELLER

Spectrum Pharmaceuticals

Boston, Massachusetts, United States

Category Company
Founded 1987
Sector Life Science
Revenue 26M USD (2023)
DESCRIPTION

Spectrum Pharmaceuticals is a biotechnology company focused on acquiring, developing and commercializing drug products with a primary focus in oncology and hematology. Spectrum Pharmaceuticals was founded in 1987 and is based in Boston, Massachusetts.


Deal Context for Seller #
Overall 1 of 1
Sector: Medical Products 1 of 1
Type: Divestiture 1 of 1
State: Nevada 1 of 1
Country: United States 1 of 1
Year: 2020 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-17 Talon Therapeutics

San Francisco, California, United States

Talon Therapeutics (fka Hana Biosciences) is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.

Buy -